Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Andò G, De Santis GA, Greco A, Pistelli L, Francaviglia B, Capodanno D, Caterina RD, Capranzano P (2022) P2Y12 inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention: a network meta-analysis. JACC Cardiovasc Interv 15(22):2239–2249
2. Chen XF, Lin HT, Huang CL (2022) Triptonide restore cisplatin sensitivity in drug-resistant gastric cancer cells by inhibiting protective autophagy. J Biol Regul Homeost Agents 36(6):1887–1896
3. Ciardullo S, Rea F, Savaré L, Morabito G, Perseghin G, Corrao G (2022) Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control study. J Clin Endocrinol Metab 107(7):E2671–E2679
4. Cui Y (2023) Clinical efficacy analysis of nutritional support therapy combined with conventional regimen in the treatment of upper gastrointestinal bleeding in patients with liver cirrhosis [J]. Chin Foreign Med J 42(30):52–55
5. Dharmarajan TS (2021) The use and misuse of proton pump inhibitors: an opportunity for deprescribing. J Am Med Dir Assoc 22(1):15–22